ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.
Jefferies Global Healthcare Conference
Presentation Time | Wednesday, June 5 at 9:30 a.m. EST |
Presenters | Raj Kannan, CEO; Louie Naumovski, Interim CMO |
Webcast link | |
Meetings | One-on-one and small group meetings: June 5, 2024 |
Management | Raj Kannan, CEO Joe Skelton, CFO Louie Naumovski, Interim CMO Tyler Ehler, Senior Director, Investor Relations |
The webcast will also be available under "Event Calendar" on I-Mab's IR website at https://ir.i-mabbiopharma.com/
For more information, please contact your Jefferies representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit https://ir.i-mabbiopharma.com/ and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.10 |
| Daily Change: | 0.12 11.77 |
| Daily Volume: | 2,679,641 |
| Market Cap: | US$89.490M |
November 14, 2024 November 06, 2024 September 16, 2024 September 10, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
